National Foundation for Cancer Research 2011 Progress Report NFCR Mission Statement The National Foundation for Cancer Research (NFCR) was founded in 1973 to support cancer research and public education relating to prevention, early diagnosis, better treatments and ultimately, a cure for cancer. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. NFCR is about Research for a Cure – cures for all types of cancer.

Table of Contents From The President ...... 1 Breaking The Code. Winning the War Against Cancer . . . . 2 Winning the War Against Cancer. A Revolution in Medicine . 4 Accelerating Discovery. Research Highlights ...... 6 NFCR Clinic For Targeted Cancer Therapies ...... 13 NFCR|NCI International Workshop Tianjin ...... 14 6th Annual Szent-Györgyi Prize for Cancer Research . . . . 15 Taking Action Against Cancer ...... 16 Extraordinary Support ...... 20 Legacy Society ...... 24

2 | NFCR Research For a Cure

From the President This is an age of cancer genetics. There is no more exciting time to be part of cancer medicine than now. By integrating molecular-based technologies, systematic tissue procurement and molecular diagnostics and genetic sequencing, the National Foundation for Cancer Research is pioneering the way in deciphering cancer’s genetic code, and translating laboratory discoveries into remarkable new therapies that target the unique genomic and cellular characteristics of each patient’s cancer.

The genetic knowledge about cancer’s inner workings is changing everything. It alters how we think about cancer biology, how we develop new anti-cancer drugs, how we test those drugs in clinical trials, how we diagnose and treat an individual’s cancer.

Genes are “broken” in cancer cells. Since 1973 the National Foundation for Cancer Research has spent over $288 million to underwrite basic discoveries about the ways broken-down genes lead to cancer. NFCR’s high impact research is paying off, but we also know there is much more we must do.

How much more? Cancer affects 11.7 million Americans directly. The disease is responsible for one out of every four deaths in this country.

NFCR-funded discoveries are the blueprints for the next generation of cancer treatments. NFCR is Research for a Cure – Cures for all types of cancer.

Those discoveries are what you make possible with your support.

Thank you and sincerely,

Franklin C. Salisbury, Jr. President

NFCR Research For a Cure | 1 Breaking the Code Winning the War Against Cancer The “black box” that was the cancer cell has been opened and, with the support of millions of Americans, NFCR researchers have pioneered the redefinition of cancer as a genetic disease, making possible new approaches to treating cancer and transforming medicine so that real hope for a cure is now within sight. NFCR scientists are at work on new anti-cancer drugs that target the very genes and signaling pathways that make a cell cancerous. These new targeted cancer therapies are proving more effective, longer lasting, and far less toxic than radiation and chemotherapy – treatments with side effects that inspire dread so deep that they are almost as feared as the cancer itself. Today, more individuals diagnosed with cancer are surviving longer than ever before. Even those who ultimately succumb to cancer live longer and experience a much better quality of life than was possible just a few years ago. Every day at NFCR, our researchers report progress in the development of promising new ways to prevent, detect and treat cancer. But until there is a cure, we will not be satisfied – too many lives are at stake. The National Foundation for Cancer Research is an innovative cancer charity, supporting cancer research in a truly collaborative way, reaching global dimensions. Since 1973, NFCR has spent over $288 million to fund “high risk/ high reward” research at universities and research hospitals worldwide. The research funding we provide is having a catalytic effect and accelerating the pace of cancer research. Today in laboratories across the United States, Germany, and China, NFCR scientists are moving cancer research toward that ultimate goal – finding cures for all types of cancer.

TARGETING TOP KILLERS TO SAVE LIVES In 2011, an estimated 1,596,670 new cases of cancer were diagnosed. As many as 570,000 people died of cancer in the United States alone. Sadly, that’s nearly 1,500 people a day. One person every minute. Nearly half of all cancer deaths in the United States are caused by four types of cancer: lung, prostate, breast, and colorectal. NFCR supports research on all types of cancer, but we have developed a comprehensive approach to support promising research that targets these four leading killers. NFCR funding helps our scientists push forward in developing new early diagnostic tools, discovering new cancer targets, and bringing more effective anti-cancer treatments to patients.

LUNG CANCER RESEARCH Seven NFCR scientists are working on ways is responsible for more than 90% of breast Causing nearly one-third of all cancer deaths to prevent prostate cancer, detect it sooner cancer deaths. with innovative technology, and tackle the in the United States, lung cancer remains the COLORECTAL CANCER RESEARCH number one killer among all types of cancer. molecular mechanisms that drive its spread Colorectal cancer is the third leading cancer NFCR provides funding to support eight including new targeted approaches and killer of both men and women in America. leading scientists from around the world novel gene therapies for treatment-resistant With NFCR support, six outstanding working to find a cure for lung cancer. Using metastatic prostate cancer.Their critical and scientists are launching attacks on this deadly the most advanced molecular technologies, innovative research will lead to better strategies disease. Their research is refining dietary means NFCR scientists are focused on several critical in prevention, earlier detection, and treatment for its prevention, identifying new biomarkers areas, including: prevention, early diagnosis, of prostate cancer. for early diagnosis, developing novel targeted personalized medicine, and the development of BREAST CANCER RESEARCH cancer therapies, and demonstrating that a simple blood test for real-time monitoring of Breast cancer is the most frequently diagnosed Traditional Chinese Medicine can alleviate the cancer. Research breakthroughs in these areas cancer and the second leading cause of gastrointestinal side effects of chemotherapy. will bring significant benefits to lung cancer cancer death in women. NFCR supports patients, improving their survival rates and OTHER TYPES OF CANCER breast cancer research in the laboratories of quality of life. 10 leading scientists. These scientists are on NFCR scientists are also working around PROSTATE CANCER RESEARCH the frontline of multiple aspects of breast the clock to find more effective treatments for many other types of cancer. Pioneering Nearly 240,900 men were diagnosed with cancer research, including: the development research is being conducted to fight pancreatic, prostate cancer in 2011 in the United of forward-looking molecular imaging ovarian, brain, liver, esophageal, gastric, States, and more than 33,700 died from it. technology that will allow earlier diagnosis, cervical, kidney, head and neck cancer, as well The 5-year survival rate for prostate cancer seeking new strategies to overcome tumor as leukemia, lymphoma, multiple myeloma, patients has dramatically increased to nearly drug resistance, developing nanocomplex melanoma, soft tissue sarcoma, and many 100%, largely due to recent advances in drug delivery technology, identifying genes others. NFCR scientists are moving cancer cancer research. However, once the cancer that control the early migration of cancer cells research toward our ultimate goal – finding has spread, it can still be fatal because there is into healthy tissue, and establishing more cures for cancer…all types of cancer. no curative treatment available at this time. effective strategies to stop metastasis – which

NFCR Research For a Cure | 3 Winning the War Against Cancer A Revolution in Medicine We are entering a revolutionary period in cancer detection and treatment that is being driven by breakthroughs in genomics and systems biology. The convergence of scientific research and emerging technologies is building an unprecedented understanding of cancer as a genetic disease, driven by abnormal genes and proteins. Twenty-first century medicine is changing how we look at cancer. For decades the disease model was confined to what we could observe in tissues and organs. Scientists are beginning to “see” biological processes in real time at the genetic, molecular and cellular levels. Scientists can now view cancer as a mechanistic disruption of the normal cycle of cell growth and death. By determining which genes and proteins are driving the cancer process in an individual patient, we can define a much more precise target for our treatment interventions. These “biomarkers” will provide earlier alerts to cancer; an advanced technology such as nanotechnology promises to create extremely small-scale devices (one eighty-thousandth the width of a human hair) that will be able to detect changes that signal the presence of cancer and deliver treatment. Each advance, new tool and technique is helping to build a future where cancer is detected early and when we can intervene before the cancer is visible under the microscope. These new fronts in the war against cancer require team work at all levels.

NFCR Mission: Non-invasive to investigate the potential of circulating Detection and Specific miRNAs as biomarkers. In a proof-of-principle Attack Plans study, Dr. Zhang identified and validated that miR-141 was a novel plasma marker NFCR Project Director Wei Zhang, a that complemented with carcinoembryonic Professor of Pathology and Cancer Biology antigen in detecting advanced colorectal at the University of Texas MD Anderson cancer patients, and that plasma miR-141 is Cancer Center has mobilized a team of 18 associated with poor survival in those patients.1 cancer scientists from 5 different countries interrogating several major cancer types, By using high-throughput technology, Wei including colorectal, ovarian, breast cancers, as Zhang has profiled close to 1,000 microRNAs well as glioma and different types of sarcomas. in blood of 40 colorectal cancer patients This is a big mission, and the team of scientists of different stages and healthy people as Wei Zhang has recruited from the U.S., controls, identifying candidate microRNAs China, and Finland is collaborating on cancer that are indicative of early stage cancer. These genomics and systems biology. Their battle plasma miRNAs markers hold important plan in the war against cancer is to find better clinical relevance and could give oncologists and especially non-invasive markers for cancer new diagnostic tools for colorectal cancer. detection, and to identify specific cancer Successful completion of Wei Zhang’s NFCR with strategies that can prevent and detect targets for better treatment. research will have a long lasting impact on colorectal cancer in its early stages, monitor management of colorectal cancer and will This is a difficult mission that requires disease progression and predict therapy likely change the current practice of colorectal persistent hard work and fearlessness of outcome. Identification of non-invasive cancer detection and prognosis. failures, but in 2011 Wei Zhang’s NFCR team markers for detection and prognosis is a and its mission plan have already reported significant area of colorectal cancer research. Ovarian Cancer Patients successes – giving patients new hope. MicroRNAs (miRNAs) are small, non-coding Survive Longer with BRCA2 RNAs that regulate expression of target genes Mutated in Tumors Discovery of a Robust Blood Marker for Metastatic through RNA interfering mechanism or Ovarian cancer is one of the most deadly Colorectal Cancer translational inhibition. gynecological cancers. As part of the Cancer Recently, accumulating evidence has indicated Genome Atlas projects, Dr. Zhang’s group Colorectal cancer remains one of the major has used an informatics method to investigate cancer-related deaths in the United States. that aberrant expression of miRNA signatures is associated with cancer development the relationships between genetic changes Progress in treating colorectal cancer has that are keys for ovarian cancer and their been hindered by suboptimal compliance and progression. Wei Zhang has begun

1 Cheng H, Zhang L, Cogdell DE, Zheng H, Schetter AJ, Nykter M, Harris CC, Chen K, Hamilton SR, Zhang W. Circulating Plasma MiR-141 Is a Novel Biomarker for Metastatic Colon Cancer and Predicts Poor Prognosis. PLoS ONE 6(3): e17745, 2011.

4 | NFCR Research For a Cure implication in treatment. A major discovery Zhang said this last aspect – called the The patients with IGF1R and/or EGFR is that women with high-grade ovarian cancer hypermutator phenotype – might be both a positive expression had significantly worse live longer and respond better to platinum- factor in the development and growth of the disease free survival and had significantly based chemotherapy when their tumors have tumor and a sign of its vulnerability. BRCA2 higher hazard of tumor development than the BRCA2 genetic mutations. The mutation is normally involved in the repair of double- negative ones. effect of BRCA2 cousin, BRCA1, on response strand DNA breaks. Cells with BRCA2 These are important findings with clinical to chemotherapy is much less. BRCA2- mutants are less capable of repair, allowing relevance because EGFR and IGF1R are mutated tumors are more vulnerable to other genetic mutations to survive and grow, targets for anti- EGFR and anti-IGF1R these DNA-damaging agents, which is really the type of genomic instability that cancer targeted therapeutic trials in several different exciting because there are numbers of drugs thrives upon. types of cancers. Examples include gefitinib, in clinical trials now that block DNA repair However, cancer cells in turn rely on DNA erlotinib, and MK-0640 in the treatment of which might prove effective against these repair to defend themselves against DNA- lung cancers. tumors in combinations. damaging drugs, such as platinum-based The IGFIR is a multifunctional tyrosine Uncovering the separate potential effects of agents. So adding drugs that inhibit DNA kinase receptor involved in several biological BRCA1 and BRCA2 mutations takes us a repair could increase the effectiveness of processes including cell proliferation, step toward a more personalized approach chemotherapy, Zhang noted. PARP-inhibitors, differentiation, and survival. Aberrant to treating ovarian cancer, and perhaps other a new class of drug in clinical trials, block activation of the IGF-I/IGF1R axis was cancers. Wei Zhang has discovered that DNA repair and may also be effective in associated with poor prognosis in many those two genes – like many others involved treating BRCA2 mutated ovarian cancer. Wei neoplasms including breast, gastric, and in DNA repair – are prime targets for Zhang’s NFCR research findings have already prostate cancers. However, there is very little further research. been validated by two independent studies information about the IGF1R expression published in Cancer and JAMA.2 Of 316 cases Wei Zhang’s team studied, 29 and its prognostic significance in MPNST. tumors had BRCA2 mutations tumors and 37 Activated IGF1R is an Therefore, Dr. Zhang’s finding that IGF1R had BRCA1 mutations. Tumors were similar Oncogenic Target in is amplified in MPNST provides important in grade and stage. Their findings included: Malignant Peripheral Nerve motivation to study this pathway in • 61 percent of patients with BRCA2 Sheath Tumor (MPNST) MPNST and to provide laboratory evidence whether inhibition of IGF1R can be a mutations survived for five years, compared Despite aggressive surgery and high dose viable approach for MPNST treatment. Wei with 25 percent of those with normal adjuvant chemotherapy and radiotherapy, Zhang’s laboratory based research provided BRCA2 in their tumors. the 5 year survival rates of MPNSTs are still evidence the inhibition of IGF1R is capable • 44 percent of those with BRCA2 mutations poor. Genetic and molecular characterization of suppressing the MPNST cell growth.3 lived three years after surgery and platinum of MPNST is needed for development of This finding offers new hope for the treatment treatment without disease progression, more effective therapies that target the driver of MPNST. compared with 16 percent of those with events of MPNST. In research funded by the normal BRCA2. NFCR-Hope Fund, Wei Zhang carried out a Dr. Wei Zhang is a powerful example of how • BRCA1 mutations in tumors were not genomic study using genome-wide microarray NFCR funding is paving the way for new associated with survival. based comparative genomics hybridization and more effective cancer treatments that save • All of those with BRCA2 mutations (aCGH) to profile genetic alterations of 53 more lives. responded to platinum chemotherapy, MPNST tissues. Bioinformatic compared to 82 percent with the normal analysis revealed that 28.3% gene and 80 percent whose tumors had (15/53) and 43.4% (23/53) of BRCA1 mutations. cases had amplification of IGF1R and EGFR genes. Furthermore, • Their response to chemotherapy lasted overexpression of IGF1R and 18 months, compared with 11.7 months EGFR proteins occurs in 85.7% for normal BRCA2 and 12.5 months for (48/56) and 58.9% (33/56), BRCA1 mutations. respectively, in the MPNSTs tested • Tumors with BRCA2 variations also are by immunohistochemistry. The hypermutants – they had more genetic IGF1R and EGFR expression had mutations – with 84 mutations per tumor significant correlation with the sample compared to 52 for normal BRCA2. tumor metastasis and/or recurrence.

2 Yang D, Khan S, Sun Y, Hess K, Shmulevich I, Sood A, Zhang W. Associations of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA 306(14):1557-1565, 2011. 3 Yang J, Ylipää A, Sun Y, Zheng H, Chen K, Nykter M, Trent J, Ratner N, Lev DC, Zhang W. Activated IGF1R is an Oncogenic Target in Malignant Peripheral Nerve Sheath Tumor. Clin Cancer Res 17(24):7563-7573, 2011.

NFCR Research For a Cure | 5 Accelerating discovery research highlights

NFCR accelerates the pace of cancer research by recognizing innovative discoveries while they are still in their infancy, and providing scientists with the “adventure” funding to substantiate their discoveries. To maximize the productivity of its cancer research programs, NFCR has established an international network of scientists constituting our “Laboratory Without Walls” – promoting the sharing of ideas and information across research institutions and engaging top research minds from a wide range of scientific disciplines. Together, NFCR’s scientists at universities and research hospitals constitute a “research collaborative” working on cancer from diverse perspectives and actively sharing ideas and information with one another. In laboratories across the Unites States, Europe, and China, NFCR scientists and their research teams are working at the leading edge of cancer research today. Highlighted here is a sampling of important research breakthroughs. To learn more about the latest research by NFCR scientists, visit www.NFCR.org.

to many different types of high quality tumor specimens, the TBCA plays an increasingly important role in cancer research. TheTB CA operates in total compliance with the highest international standards, and is governed by a TBCA Steering Committee made up of leading scientists from the NCI, Chinese Ministry of Health, as well as universities, research hospitals, and biopharmaceutical companies in the United States and China. Brian Leyland-Jones, M.D., Ph.D. – Xi-Shan Hao, M.D. – TMUCIH- Consortium for Clinical Diagnostics NFCR Joint Tissue Banking NEW BLOOD TEST FOR CANCER (CCDx), Atlanta, is revolutionizing Facility, Tianjin Medical University, cancer therapy and diagnostics through Tianjin, China. Well-characterized the use of biomarkers. With the growing tumor specimens, carefully gathered and urgent need for biomarker profiling and preserved in a well-managed and validation in cancer research biorepository, constitute one of the today, the Consortium for Clinical most valuable resources for cancer Diagnostics (CCDx) is a partnership researchers. Genetic data from of scientists at research institutions tumor specimens, coupled with the and biopharmaceutical companies development of technologies to assay dedicated to facilitating genomic the molecules and pathways in tumor research and developing new diagnostic cells, allow researchers to gain deeper tools. CCDx provides a centralized understanding of the roles cancer-related infrastructure and expertise in genomics genes, proteins and pathways are playing and molecular imaging as well as in different types of cancer, and are translational medicine. The Consortium revolutionizing modern cancer therapy. Daniel A. Haber, M.D., Ph.D. – provides key capabilities in all aspects Scientists at the TMUCIH-NFCR Massachusetts General Hospital, Boston, of predictive medicine, including Joint Tissue Bank collect and maintain and his team of scientists have developed identification and validation of disease biospecimens (tumor tissues and a revolutionary way to detect and susceptibility genes and genetic matching blood samples) from cancer capture circulating tumor cells (CTCs) signatures, pharmacogenomics, and the patients fighting all types of cancer. This in the blood. This technology may development of medical response tests rapidly growing biorepository includes provide doctors with an unprecedented as well as new and improved diagnostic more than 24,000 fresh-frozen tissue means of rapidly detecting invasive tests – especially as they relate to cancer. samples and over 14,000 blood samples. cancers by using an easily administered blood test. Knowing about the presence The TMUCIH-NFCR Joint Tissue and the genetic features of cancer cells Bank is part of an NFCR Tissue Bank in a patient’s blood may enable the Consortium in Asia (TBCA), a source physician to identify and prescribe of biospecimens essential to forward- targeted anti-cancer treatments early thinking cancer research. NFCR on, before the disease can spread to and provides consortium members access then reside in another organ. Such a test to a web-based biospecimen locator, could also enable doctors to monitor the enabling cancer researchers to determine effectiveness of their patient’s treatment the availability of suitable biospecimens. and make any necessary treatment By providing cancer researchers access changes, increasing the positive effect of all cancer therapies.

NFCR Research For a Cure | 7 TARGETING THE and the technology to successfully AGGRESSIVE BRAIN CANCER, deliver genes to the central nervous GLIOBLASTOMA system. This research will expand the technology and its application to cancer. ANTI-CANCER DRUG DESIGN AND DISCOVERY

Susan Band Horwitz, Ph.D. – Albert Einstein College of Medicine, Bronx, is deciphering how tumors Webster K. Cavenee, Ph.D. – Ludwig develop resistance to Taxol, and is developing new strategies to overcome Institute for Cancer Research, La Jolla, the drug resistance problem in tumors. demonstrated in glioblastomas of two Her research has shown Taxol and patient cohorts that a modification Alanna Schepartz, Ph.D. – Yale the natural product, discodermolide, of tumor suppressor protein, PTEN, University, New Haven, has developed have complementary effects in is an independent indicator of poor anti-cancer beta-peptide inhibitors to inhibiting cell division, explaining why prognosis. PTEN modification in address one of the biggest challenges combining the two drugs can enhance tumors is associated with and may in drug discovery. Beta-peptide the therapeutic activity of Taxol and cause the upfront and acquired tumor inhibitors represent a new generation may even reduce the emergence of resistance to the targeted therapy, of anti-cancer drugs that are highly drug resistance. In the past year, her EGFR inhibitors. Current work is effective and specific in targeting almost team designed and synthesized a small determining the molecular players of any cancer-related protein-protein library of Taxol-discodermolide hybrid PTEN modification and linking them interaction. Currently, Dr. Schepartz is molecules and showed that selected with different subtypes of gliomas. This designing beta-peptides against protein ones enhance antiproliferative effects in ongoing research is highly significant interactions involving PTHrP, a protein cancer cell lines. A single drug would as it will lead to the logical selection involved in breast cancer metastasis to eliminate complicated dosing that is of patients and therapies, improving bone. Beta-peptide inhibitors are a new necessary when two drugs are used in patients’ initial response to therapy as platform technology that may positively combination. The availability of such well as extending patients’ responses impact the treatment of all major types hybrid drugs for the treatment of lung, after a relapse. of cancer. breast, and ovarian cancers could make a William Jorgensen, Ph.D. – significant difference for patients whose tumors are resistant to Taxol. Yale University, New Haven, is a renowned leader in developing computational methodology and computer software to rapidly and cost- effectively develop novel targeted drugs. Dr. Jorgensen has successfully applied his methodology to rapidly obtain a novel, potent anti-HIV drug and an anti-inflammatory agent for arthritis. In 2011, his team has generated and optimized some potent lead compounds that inhibit FGFR (Fibroblast Growth Factor Receptor), which is implicated Ronald G. Crystal, M.D. – Weill in pancreatic, breast, and other cancers. Medical College of Cornell University, With further testing and refinement, New York, is conducting research these potential novel targeted drugs on using recombinant proteins and may be rapidly brought into the clinic, Paul Schimmel, Ph.D. – The Scripps antibodies to develop gene transfer giving pancreatic patients hope that their Research Institute, La Jolla, and treatments for glioblastoma as well as cancer can be effectively treated. colleagues are seeking to understand why other central nervous system disorders. human aminoacyl tRNA synthetases, Dr. Crystal’s lab has developed strategies which are among the essential enzymes

8 | NFCR Research For a Cure involved in the protein synthesis PERSONALIZED MEDICINE machinery found in all organisms, have distinct additional vital activities that are involved in pathways relevant to treating cancer and other diseases. In 2011, research continued on their discovery of how one tRNA synthetase stimulates production of platelets. The tRNA synthetase is being developed to treat thrombocytopenia or low number of platelets that causes abnormal bleeding – also a common side-effect of chemotherapy. tRNA synthetases are becoming a new class of medicines. Because they are based on molecules Laurence Hurley, Ph.D., Daniel found naturally in human cells, Von Hoff, M.D. – NFCR Clinic they should have minimal untoward Waun Ki Hong, M.D. – MD Anderson side effects. Cancer Center, Houston, and his team for Targeted Cancer Therapies, TGen, are using the novel technology of Phoenix, are developing new targeted Next-Generation Sequencing (NGS) to cancer therapies and improving the identify aberrant genes and molecular treatment efficacy of existing therapies. pathways associated with non-small cell In the past year, these researchers lung cancer (NSCLC.) In a pilot project, continued their work on a new viable the researchers used NGS on small tissue drug target for pancreatic cancer, specimens from needle core biopsy and YAP1, a gene that acts on other genes identified more than 3,500 genes as to promote pancreatic cell growth. differently expressed in the tumor tissue In another research arena, the team as compared to normal lung tissue. published their work that demonstrated the combined use of an inhibitor to Using sophisticated software for further MEK protein with Erlotinib, the FDA- analysis, several pathways known to be approved targeted therapy for pancreatic involved in NSCLC progression were cancer, had enhanced efficacy in cell significantly overrepresented in the lines or tumor models of pancreatic tumor, as well as other abnormalities in Alan C. Sartorelli, Ph.D. – Yale cancer. These results are highly key cell functions. Importantly, NGS University School of Medicine, translational, as further evaluation of will allow Dr. Hong’s team to identify New Haven, is a world-renowned the combination treatment may result very rare genetic changes which are pharmacologist who designed in new and improved treatment for expected in lung tumors, a critical “next Cloretazine™ (now known as Onrigin™), patients with pancreatic cancer. step” toward more personalized medicine a drug demonstrating promising and, therefore, more effective therapies treatment benefits for patients with for patients with lung cancer. Acute Myeloid Leukemia (AML), other types of leukemia, brain tumors, lung Kathryn B. Horwitz, Ph.D. – and other types of cancer. Onrigin is University of Colorado Anschutz a member of a class of chemotherapy Medical Campus, a renowned leader agents called guanine O6-targeting is hormone-dependent breast cancer, is drugs which modify cellular DNA. To identifying the molecular cancer-causing make Onrigin and similar agents target factors that define the multiple groups only cancer cells, Dr. Sartorelli has of cancer cells that make up each breast designed an inactive drug that converts tumor. Her vision is that each major to an active one only in low-oxygen or subpopulation of cancer cells should hypoxic cancer cells. With his innovative be therapeutically targeted so that design, Dr. Sartorelli envisions these new none is left to regrow after treatment. targeted drugs will be effective in tumors Her team’s research results on the that have been resistant to therapeutic characteristics of these cancer subgroups Esther H. Chang, Ph.D. – intervention, providing hope to AML will allow development of a cocktail of Georgetown University, Washington, and other cancer patients that their therapeutics that, after being matched DC, has developed a nanoscale, cancer can be effectively treated. to each woman’s tumor, will blast each liposome-based tumor targeting drug cancer cell subgroup into oblivion. delivery system that can carry anti- cancer agents directly to both primary and metastatic tumor cells, significantly

NFCR Research For a Cure | 9 enhancing a tumor’s sensitivity to how these genes and their proteins chemo- and radiation therapy. Dr. function to suppress metastasis in Chang and her team successfully order to develop new anti-metastasis delivered tumor suppressor gene p53 therapies. Recent results indicate that and anti-HER2 siRNA to tumors, KISSI proteins are secreted from tumor including breast and pancreatic tumors. cells and cause nearby immune system In 2011, an early phase 1 clinical trial cells to secrete factors that “feedback” on showed the p53 nanocomplex proved to to the tumor cell to thwart its growth. be a safe, non-toxic potential targeted The researchers are working tirelessly cancer therapy in treating patients with to pinpoint all the molecular players in several types of solid tumors, and is now this feedback process that suppresses advancing to a phase 1B clinical trial. metastasis. The data generated will be crucial for translating their laboratory ANTI-ANGIOGENESIS discoveries into new anti-metastasis Rakesh K. Jain, Ph.D. – Massachusetts SHUTTING DOWN CANCER therapies for cancer, including breast, General Hospital, Boston, is discovering prostate, colon, ovarian, and pancreatic new ways of preventing resistance to cancers and melanoma. anti-angiogenic therapy in glioblastoma patients. Although some patients CHINESE HERBAL initially respond positively to this MEDICINES AS ADJUNCT TO therapy, in all cases the tumors ChemoTHERAPY eventually regrow. Identification of biomarkers that indicate tumor progression during therapy is urgently needed to guide the development of new treatments that will stop cancer growth. Recently Dr. Jain’s team identified, for the first time, that biomarkers, PDGF-C and c-Met, are highly expressed in Harold F. Dvorak, M.D. – Beth Israel patients’ glioblastoma cells after anti- Deaconess Medical Center, Boston, angiogenic therapy. Research continues won the inaugural Szent-Györgyi to evaluate these biomarkers and Prize for his discovery of the Vascular identify new potential candidates that Permeability Factor/Vascular Endothelial may drive the tumor to progress and Cell Growth Factor (VPF/VEGF). The cause the resistance to the therapy. New growth factor VEGF plays a central effective treatments can be developed, Yung-Chi Cheng, Ph.D. – Yale role in angiogenesis or the formation of giving patients renewed hope of University School of Medicine, New blood vessels in and around malignant winning the battle against this aggressive Haven. The therapeutic effects of tumors. Dr. Dvorak’s work has led to brain cancer. traditional Chinese medicines have the development of anti-angiogenic been documented for centuries but have metastasis suppressor therapies, a new generation of anti- been regarded by modern medicine as geneS cancer drugs that target tumor blood “alternative therapy” because there was vessels. Recently, he has demonstrated Danny Welch, Ph.D. – NFCR little scientific proof that they could that the therapeutic effects of individual Center for Metastasis Research, work. For the last 10 years, with NFCR anti-angiogenic drugs vary among University of Kansas Cancer Center, support, Dr. Cheng has explored the different types of tumor blood vessels. Kansas City, is addressing metastasis, therapeutic properties of PHY906, a His team has also identified several the most lethal aspect of cancer, Chinese herbal medicine formula of four potential new therapeutic targets for which is related to more than 90% of herbs described 1,700 years ago. inhibiting angiogenesis. Dr. Dvorak’s all cancer deaths. Center researchers Recently completed phase I/ IIa clinical work has significant clinical implications and collaborators have discovered six trials demonstrated that combining for the research community, as it clarifies metastasis suppressor genes, including PHY906 with chemotherapy alleviates the relative strengths and weaknesses of KISS1, which when expressed in the unpleasant gastrointestinal anti-angiogenic drugs for treating cancer, spreading cells, renders the cells side effects of chemotherapy given guiding the development of this critical incapable of growing into a secondary to colorectal cancer patients. component of effective targeted therapy. tumor. Researchers focus on identifying

10 | NFCR Research For a Cure A randomized, double-blind phase II treatment of leukemia and lymphoma. trial will begin in 2012 and it is possible The safety and feasibility of this novel that PHY906 will improve the quality immunotherapy were demonstrated in of life and increase survival time of a phase I clinical trial in patients with CD19+ lymphoma. patients undergoing chemotherapy. PHY906 could become one of the first To further improve the safety of this FDA-approved oral herbal medicines immunotherapy, Dr. Cooper has for anti-cancer treatment. This developed an innovative method that breakthrough represents a paradigm enables the engineered immune cells to target only leukemia or lymphoma cells, shift in the way the cancer research thereby limiting harmful targeting of community thinks about traditional normal cells. Plans are underway for the Chinese medicine. It opens the door next-generation clinical trial in which a for new approaches to treating cancer donor’s immune cells will be engineered using these ancient medicines and Wayne Marasco, M.D., Ph.D. – to target only cancer cells once infused potentially gives physicians new and NFCR Center for Therapeutic back to patients during their bone more effective options for treating many Antibody Engineering, Dana-Farber marrow transplantation. The improved cancer patients. Cancer Institute, Harvard Medical safety and specificity will result in more successful transplantations. School, Cambridge, is discovering and cancer terminator virus engineering therapeutic antibodies for clinical applications in cancer. TARGETING OVARIAN The Center has established a library CANCER containing 1.6 billion different human sFv antibody-displaying phages, a tremendous resource for developing monoclonal antibody-based targeted therapies. Center researchers have identified high affinity human sFv antibodies against a unique domain of a selected cancer target for renal cell carcinoma. These reagents are being developed as new immunotherapies and diagnostic tools for kidney cancer patients who currently have no effective cancer treatment. Recent research Paul B. Fisher, M.Ph., Ph.D. – indicates increasing types of cancer cells Virginia Commonwelath University also have the selected target suggesting Robert C. Bast, Jr., M.D. – MD School of Medicine, has developed a these new antibodies may have a broader Anderson Cancer Center, Houston. Less novel gene therapy to treat early stage use in cancer therapy. than one-half of women with ovarian and metastatic prostate cancer. cancer are sensitive to paclitaxel. This This new therapeutic is a genetically commonly prescribed chemotherapeutic reprogrammed virus, designed to agent stabilizes microtubule proteins to specifically infect and destroy only inhibit cell division and causes cells to tumor cells, leaving normal cells collapse. Finding therapeutic approaches unharmed. The virus also delivers a to enhance the effects of paclitaxel would improve the outcomes significantly for natural product of our immune system, women with ovarian cancer. interferon gamma, which will seek out and destroy cancer cells that have Through a large screening effort, Dr. metastasized. This powerful new gene Bast’s team has identified genes for two groups of proteins, kinases and therapy approach may soon be used to transporters, that when inhibited with treat patients in a clinical trial. siRNAs, sensitized cancer cell lines to the killing effects of paclitaxel. Most of Laurence J.N. Cooper, M.D., the kinases also stabilized microtubules Ph.D. – MD Anderson Cancer Center, similar to paclitaxel while a few candidate kinases and transporters did Houston, is developing new forward- not. Ongoing research is testing whether looking technology which genetically different combinations of siRNAs that engineers human immune cells for the enhance paclitaxel sensitivity through

NFCR Research For a Cure | 11 different mechanisms provide additive or CANCER PREVENTION Helmut Sies, M.D. – Heinrich- synergistic anti-cancer effects. Inhibition Heine-Universität, Düsseldorf, of select kinase and transporter genes Germany, is well recognized for his that enhance sensitivity to paclitaxel discovery of the skin cancer prevention may become a promising new treatment effects of the micronutrient, lycopene, approach for women with ovarian the antioxidant found in tomatoes cancer. and carrots. Dr. Sies continues to pioneer research in the critical area of IDENTIFICATION OF NEW micronutrients of which one focus is THERAPEUTIC TARGETS on selenium, a trace metal essential for good health. Dietary or supplemental selenium is incorporated into selenoproteins – critical cell proteins that have anti-oxidation functions. Many intervention trials suggest a beneficial impact of selenium for prevention and Michael B. Sporn, M.D. – therapy of prostate, colon, lung, and Dartmouth Medical School, Hanover, is liver cancer. developing new triterpenoid compounds for the prevention and treatment of Dr. Sies’ recent results indicate cancer. His highly fruitful research that the selenomethione may be a has resulted in several triterpenoid safe dietary supplement to increase compounds which have potent our body’s production of anti- preventative effects against liver cancer, oxidative selenoproteins. In contrast, melanoma, and highly aggressive lung sodium selenite and methylseleninic cancer. Two of these agents have been supplements carry a risk of developing Curt I. Civin, M.D. – University of Type-2 diabetes. Maryland, Baltimore, is elucidating evaluated in clinical trials for cancer treatment. The Sporn team is now how the survival, proliferation, and molelecular imaging differentiation of normal and malignant demonstrating these agents are effective blood stem cells are regulated, with in preventing pancreatic cancer in tumor Jim Basilion, Ph.D. – NFCR Center the goal of translating these findings models. Anti-inflammatory properties of for Molecular Imaging, Case Western these compounds are being identified. into useful clinical tools. Dr. Civin’s Reserve University, Cleveland, is With continued success, triterpenoids team discovered a set of microRNAs building a new technology platform could be rapidly translated to the functioning as powerful “master utilizing molecular imaging for early clinic to evaluate the effectiveness of switches” that control the maturation of detection and improved treatment these compounds in preventing this adult blood-forming stem cells. Breaking of many types of cancer. Utilizing an devastating disease among people who the code of blood cell maturation may entirely new technique that permits are known to be at high risk. one day enable scientists to grow new the simultaneous imaging of multiple blood cells for transplantation into Janos Ladik, Ph.D. – University molecular markers, scientists in this patients with cancer or other bone Erlangen-Nürnberg, Erlangen, Center make it possible to identify marrow disorders. The researchers Germany, is conducting research on cancer at a very early and more treatable are further deciphering how two DNA intercalating agents – anti-cancer stage, significantly improving patients’ microRNAs may also function in drugs that wedge themselves into the chances of survival. Technologies normal blood cells to suppress the DNA double helix to interfere with cell developed at the Center can also help development of leukemia. Stay tuned division and the making of RNA and surgeons determine tumor margins for the development of the clinical proteins. Cells that are rapidly dividing, during an operation and make it possible potential of “microRNA mimics” for such as cancer cells, are inhibited by for more complete surgical removal of treating leukemia, as these scientists certain intercalating agents. Dr. Ladik infiltrated tumor tissue such as brain unravel the functions of these master uses theoretical physics and super cancer. One molecular imaging approach biological switches. computers to investigate the use of DNA is currently being tested in a clinical intercalating agents as cancer preventive trial to assess if margins of lumpectomy agents, inhibiting the formation of specimens from the breast are free of cancer-causing mutations and thereby cancer. Success with this technique preventing cancer initiation. could dramatically reduce the current re-excision rates of 40-50%.

12 | NFCR Research For a Cure NFCR clinic for targeted cancer therapies Next-Generation Sequencing techniques are being used by clinical researchers at the NFCR Clinic for Targeted Cancer Therapies in Scottsdale to identify and match the genetic makeup of a patient’s cancer with anti-cancer treatments that target that patient’s cancer. So far, this new approach to treating cancer reaches only a small segment of cancer patients, but for them, these new approaches to treating cancer are stunningly effective. This evolving genetic knowledge about cancer’s inner workings is changing everything. It alters how we think about cancer biology, how we develop new drugs, how we test those drugs in clinical trials, how we diagnose and treat an individual’s cancer.

For more than half a century, treatment Targeted cancer therapies are a new class of genetic makeup with anti-cancer treatments, of invasive cancer has relied mainly on anti-cancer drugs that home in specifically on the NFCR Clinic for Targeted Cancer surgery, chemotherapy, and/or radiation cancer cells, disrupting the molecular signals Therapies represents the future of medicine therapy. These approaches to treating cancer that sustain them. This is a new approach to where information gleaned from the complex have had the effect of attacking cells in the treating cancer, and every month researchers assemblage of an individual’s DNA can be body indiscriminately, since most of these are identifying another genetic marker that used to target deadly tumors, even among treatments cannot distinguish healthy cells says “treat here.” If a patient is treated based patients with rare cancers. from cancer cells. These approaches are like on that target, the chance of having an anti- Just this year, Dr. Von Hoff sequenced the entire mowing a lawn overrun with dandelions – it tumor response isn’t 5 percent, it’s upwards DNA and RNA of metastatic adenocarcinoma looks as though the weeds are gone, but the of 80 percent.1 of the lung from a patient who never smoked. roots are intact and the dandelions come back. The patient, a 61-year-old woman whose lung In addition, due to the distinct genetic make- cancer had entered her bloodstream and spread up and environment of each individual, those to other parts of her body, had been treated with who appear to have the same type of cancer several types of chemotherapy. may respond very differently, and sometimes Dr. Von Hoff used Whole Genome adversely, to a potentially beneficial treatment. Sequencing, also called Next-Generation By many estimates, fewer than 25% of cancer Sequencing, to look at all 3 billion chemical patients benefit from the drugs they take as bases of the patient’s normal DNA, as well as part of traditional chemotherapy, and the rest the patient’s tumor DNA. Researchers at the merely experience the side effects caused by Personalized Medicine Research Clinic went these highly toxic chemicals. Even worse, these further by examining the normal and tumor treatments are extremely expensive. The dollars RNA for whole transcriptome sequencing, spent on treatments that don’t work, and lost which can reveal the possible defects in opportunities for potentially more effective how proteins are synthesized. This provided therapies, are staggering. an even more intricate view of the tumor’s But this is an age of cancer genetics, and we Daniel Von Hoff, M.D. biological make up and what might have led now have new molecular weapons in the war to her cancer. against cancer. More and more, we can test an individual’s The results of the patient’s sequencing were Now there is hope. cancer genes to determine the most effective discussed with her treating oncologist who Because of genetic research, we now treatment and predict the likelihood of used this data along with other information understand that cancer is not one disease, but metastasis and recurrence, Clinical researchers to help decide the best course of future many diseases with different combinations at the NFCR Clinic for Targeted Cancer treatment. A review of well-characterized of genetic mutations that respond differently Therapies in Scottsdale are using genetic cancer-related genes found that a mutation to therapies. Doctors can detect and target sequencing of a patient’s tumor genoma resided in the TP53 gene, a mutation in the a tumor’s underlying genetic malignancy versus normal genome to clearly characterize tumor (one base change in the genetic code), which is often driven by just one or two the potential targets in an individual and that the mutation was always present in mutated genes in a cancer cell, without the patient’s tumor. both the DNA and RNA. Such a mutation widespread collateral damage to healthy tissue Clinic Director, Daniel Von Hoff, M.D., can halt the creation of tumor suppressor of traditional radiation and chemotherapies. is sequencing, or spelling out, the DNA of genes and result in the generation of a tumor. It is the difference between debugging a patients with cancer – spelling out all 3 billion Interestingly, the cancer specimen showed no computer by tinkering with the hardware letters in their DNA, to help determine the loss of heterozygosity, in which one side of the versus reprogramming the software. best course of treatment. Through Dr. Von DNA’s chromosome becomes inactive because of a mutation. But we cannot wait another three decades for Hoff’s pioneering efforts in whole genome these discoveries to reach cancer patients who sequencing as a tool for matching a patient’s need them now.

1 JR Nevins, “Genomic Signatures to Guide the Use of Chemotherapeutics,” Nature Medicine, November 2006, p. 1294.

NFCR Research For a Cure | 13 NFCR|NCI International Workshop Tianjin

This is an age of cancer promote resource genetics, calling for new sharing and team strategies and new tools. science to facilitate multi-institutional, Promising new cancer high-throughput treatments rely on genomic and identifying the specific proteomic research. molecular profile of each tumor and An overriding theme understanding the of the workshop was susceptibility imparted one of “collaboration, by the patient’s communication, and underlying genetics, sharing credit.” The to optimize through workshop agenda pharmacogenomics the highlighted the role therapy that will be of biospecimens in most effective and least translational research toxic. Such targeted and molecularly cancer therapies will be informed medicine. more successful and less Scientists discussed costly than conventional the importance of treatments. However, robust information the success of these systems, and new cancer treatments emphasized how depends upon having this data must be high-quality human interoperable with biospecimens for clinical and research screening, monitoring, data systems. The and research, so that workshop featured findings at the bench examples of successful can be translated into collaborations that therapeutic regimens for have contributed the patient. to the development of high-quality In this way, cancer tissue biorepositories in can be considered the Tianjin, Shanghai, center of the molecular- and Japan. medicine universe, and as biospecimen Invited participants quality underpins from China, Finland, the movement to Japan, Singapore, personalized molecular medicine, collaborative Institute and Hospital hosted a “U.S.-China the United States, and Vietnam included efforts – including private-public partnerships Workshop on Common Standards for biospecimen researchers, biorepository like NFCR’s Tissue Bank Consortium of Biorepositories and Biospecimen Research” in managers, pathologists, bioinformaticians, and Asia – can accelerate drug discovery and help Tianjin, China. This international workshop epidemiologists, as well as representatives of defeat cancer. was designed to advance cancer research pharmaceutical companies and government officials. Additional support was provided Accordingly, in partnership with the by raising awareness about the importance by Pfizer, Amgen, and Eli Lilly, as well U.S. National Cancer Institute Office of of developing and implementing common as Novartis, Takeda Millennium, Abbott Biorepositories and Biospecimen Research, standards for biorepositories internationally. Laboratories, and the Asian Fund for the National Foundation for Cancer Research Great steps were made to develop an Cancer Research. and the Tianjin Medical University Cancer interoperable biorepository infrastructure to

14 | NFCR Research For a Cure 6th annual szent-györgyi Prize

The 6th Annual Szent- Her experiments showed Györgyi Prize for Progress that when stem cells from in Cancer Research was a teratocarcinoma, a type awarded to Beatrice of tumor derived from a Mintz, Ph.D., Professor “multipotent” stem cell, were and Jack Schultz, Chair transferred into a normal in Basic Science at the early embryo, those cells Fox Chase Cancer Center contributed, along with host in Philadelphia, PA. The cells, to development of Prize was presented to Dr. the wide range of normally Mintz on March 8, 2011 functioning tissues. This at The Westin New York “normalization” of the tumor at Times Square during an stem cells is attributable to the award ceremony featuring normal microenvironment in a keynote address by which they were placed, and Lewis C. Cantley, Ph.D., has influenced many fields Professor, Beth Israel of biology. Deaconess Medical Center. The first transgenic model “The Szent-Györgyi of malignant melanoma was Prize is an honor to produced in Dr. Mintz’s lab. receive in celebration This genetically engineered of Dr. Szent-Györgyi’s model is currently the only extraordinary vision and one that encompasses different accomplishments,” said Dr. subtypes of primary skin Mintz. “This recognition melanomas, which undergo is an encouragement for widespread metastasis, ongoing research, public thereby mirroring the disease education about cancer, in people. and improved treatments. The Prize is named in I am deeply pleased to find memory of 1937 Nobel myself in the company Prize-winning scientist and of previous awardees NFCR Co-Founder, Albert whose work I have long Szent-Györgyi, M.D., Ph.D., admired.” Dr. Mintz’s discoveries have a broad last year’s Prize winner. “Her contributions to who won the Nobel Prize for Physiology relevance for cancer research and for new the field of cancer research are remarkable.” and Medicine in 1937 for his discovery cancer treatment prospects. Dr. Mintz first analyzed development by of vitamin C. In 1973, Dr. Szent-Györgyi Dr. Mintz received the Prize for her discoveries producing chimeric individuals in which helped change the face of cancer research of the relationship between development and genetically different cells coexisted throughout by co-founding NFCR, to provide scientists cancer, based on construction and analysis of life. She found that normal development is with the financial support necessary to pursue chimeric and transgenic mouse models. Her based on an expanding clonal organization in innovative, basic cancer research. The Prize work has enabled the study of cancer and which a succession of small numbers of stem is awarded annually to a scientist, nominated other genetic diseases to be carried out within cells are competent to divide or to differentiate by colleagues or peers, who has contributed the framework of the whole organism. further. In cancer, the differentiation option is outstanding, substantial research to the fight against cancer and whose accomplishments “Dr. Beatrice Mintz’s groundbreaking research diminished, while the capacity to divide may have helped improve treatment options for has changed the way scientists are able to increase. Thus, cancer may be regarded as an cancer patients. investigate the progression and metastasis of aberration of development. cancers and shed light on this disease,” said Dr. Mintz was also the first to discover the The 6th Annual Szent-Györgyi Prize Selection Peter K. Vogt, Ph.D., Chair, 6th Annual importance of the microenvironment in Committee was Chaired by Peter K. Vogt, Szent-Györgyi Prize Selection Committee, and the behavior of stem cells in the organism. Ph.D., and Co-Chaired by Sujuan Ba, Ph.D.

NFCR Research For a Cure | 15 Stretch to the Cure Some run, some Taking Action walk, but the bold STRETCH their way to the cure! For the second year, The National Foundation for Cancer Research partnered with Yoga and Pilate Studios across America to Stretch for the Cure. From September 19–25, studios and instructors participated by distributing educational materials on cancer prevention to their students, and donated proceeds raised in each of their classes to NFCR. Stick it to Cancer High school and collegiate field hockey teams from across the country continue to show their support and grow Stick it to Cancer events. The field hockey community is an amazing group to work with and they continue to raise awareness and support in creative ways. From August 12–19 in Louisville, KY, Ballard, Christian Academy, Collegiate, Eastern, Kentucky Country Day, Manuel, North Oldham, and Presentation’s Varsity Field Hockey teams participated in a preseason tournament that raised over $7,000 for NFCR cancer research. Special recognition goes to Amy Charasika (Kentucky Country Day’s coach) and Jenny Dobbins (former coach and parent) for their organizing and fundraising efforts, in recognition of their friends and family who have been affected by cancer. ”The tournament,” Jenny said, “brings everyone together from different schools for a great cause. It shows that we can be rivals on the field, but after the game we are all friends and we do what we can to support each other and give back to our community.”

Tournament Winners from Louisville Collegiate School.

New Answers for Cancer: NFCR Donors are helping us solve the Cancer Puzzle –helping us solve the scientific mysteries of cancer to bring promising new therapies to patients.

16 | NFCR Research For a Cure KICK cancer program Against Cancer NFCR’s Kick Cancer program is an incredible success. High school, college, and even professional teams join together in the fight against cancer. Participants sell t-shirts, hold bake sales, release balloons to honor and remember their loved ones, and distribute materials to raise cancer awareness. Even the smallest gestures make a difference, and we are grateful to work with such caring individuals and communities.

Boston Aztec Breakers Reserves, Woborn, MA

Beat Cancer With a Bat During the 2011 Girls Softball Season, teams from around the nation chose to Beat Cancer with a Bat by hosting fundraisers during their games and tournaments. The National Foundation for Cancer Research was honored to be a part of each of these girls’ seasons, and is hopeful that they will continue their contributions in the fight to find cures for all types of cancer. Beat Cancer with a Bat was one of NFCR’s top sports fundraisers in 2011, and we are excited for the future of this growing program.

5 Star Sports Camp in Maryland.

NFCR Research For a Cure | 17 The Lucy Fund for Starling, WJLA TV ABC 7 News Anchor, and Metastatic Breast co-chaired by Mrs. Powell Smith Lindsay and Cancer Research Mrs. Claudia H. Neal, featured some of the area’s most prominent women. This Annual Luncheon has become a spring ritual in DC, drawing hundreds of women and raising hundreds of thousands of dollars since its inception to fund breast and ovarian cancer research in the Capital region. Long-time Daffodils and Diamonds Board member and three-time cancer survivor, Lynn Novelli, strongly believes “that NFCR’s Sujuan Ba, NFCR with Lucy research on early detection and expanding cancer treatment options will make it possible The Daffodils and Diamonds Luncheon Lucy, a college professor and mother of two, was for cancer patients to live longer, healthier lives. supports breast and ovarian cancer research, diagnosed with metastatic breast cancer in 2008 NFCR’s approach of leaving no stone unturned education, and prevention. Daffodils and at age 42. Says Lucy, “While there was plenty in the search for cures is the right way to go.” Diamonds has the ability to work “hands-on” to read about breast cancer, I found almost with NFCR to fund research locally. nothing about stage IV. It was as if I didn’t exist, Cancer is so close to home for all of us and This year’s event featured fashions from like I was already a lost cause.” Lucy turned her this event is really all about celebrating the Lord & Taylor, with jewelry provided by passion for fighting metastatic breast cancer survivors, remembering those who have passed Lynn Novelli. into something bigger – The Lucy Fund for on, and committing ourselves to continuing Metastatic Breast Cancer Research at the the important fight against cancer. “We all Companies contributing to the success of the event National Foundation for Cancer Research. have to dig a little deeper and resolve to keep included Lord & Taylor, Gucci, John Greenan working to conquer one of the world’s most & Sons Jewelers, Marriott, Bloomingdales, Ritz The Lucy Fund has raised $110,000 for prevalent life-threatening diseases,” said 2010 Carlton, Georgetown Cupcake, Fuddruckers, metastatic breast cancer research – a form Co-Chair Nancy Cole. Dave & Busters, and others. of the disease that took the life of Elizabeth Edwards and one that urgently demands more research funding. “While there is no cure,” Janis and Love Use Star Power and Beautiful says Lucy, “there are therapeutic options, and Music to Advance Cancer Research if we can get more research and attention focused on stage IV, it may one day be possible Tim Janis, an award-winning composer, to treat stage IV like a chronic, rather than a pianist, and conductor, decided the cancer problem was just too serious deadly, disease.” for him to remain on the sidelines. He Funds raised through the Lucy Fund support approached NFCR with an idea. “If I Danny Welch, Ph.D., Director of the NFCR make a commitment to NFCR, a sizable Center for Metastasis Research at the University commitment, could you use my support of Kansas. He and his collaborators have as a challenge to encourage other donors discovered six genes that suppress the spread of to come on board and join in the battle certain types of cancer – including breast cancer. against cancer?” NFCR’s answer was an enthusiastic, “Yes!” But in truth, we didn’t realize Right now, Welch and his team are working how powerful Tim’s Matching Gift Challenge would be in generating new support for to understand the mechanisms that govern cancer research. how these genes work and, more importantly, In the three years since the first Matching Gift Challenge, NFCR’s loyal donors have considering ways that these discoveries can be given over $1.5 million. rapidly translated into new targeted therapies Tim’s friends in the music world have not remained in the audience, either. Actress for patients whose breast cancer has spread. and Rock and Roll Hall of Fame singer Darlene Love reached for the microphone and Daffodils & Diamonds developed a collaborative album with Tim, “Celebrating America at Christmas.” The unique blend of these two mega-talented artists resulted in one of the most beautiful Diamonds glittered and daffodils bloomed holiday albums around, and one that is sure to be timeless. while beautiful models strutted the latest fashions down the runway at the 30th Annual “Nothing is more valuable than the gift of good health,” says Tim. “Without it, Darlene Daffodils and Diamonds Luncheon at the and I could not enjoy those things we love most in life, and our greatest love is music.” Congressional Country Club in Bethesda, on Darlene added, “It was such a natural thing for us to partner together…and we are both very proud to have the proceeds committed to such an important cause.” March 10, 2011. The event, emceed by Alison

18 | NFCR Research For a Cure The Muriel Ettinger golf for a cure Memorial Fund Allan Ettinger of Chicago lost his mother, The 8th Annual Golf for a Cure Classic was held on September 12, 2011 at Muriel, when he was just 14 years old after Kenwood Golf and Country Club in Bethesda, MD. 140 players from as far away her long battle with lung cancer. “I will never as Massachusetts, Illinois, and Nebraska gathered for a warm and sunny day of golf. forget those painful memories of seeing her After showcasing their talent in the putting contest, golfers enjoyed a hearty BBQ suffer both from cancer and from the side lunch before hopping in their carts to conquer the golf course. Following a day of effects caused by chemotherapy.” Cancer straight drives and birdies, golfers returned to the clubhouse where they enjoyed kills almost half a million Americans each dinner, followed by Silent and Live auctions, and Raffle drawings throughout the year, and lung cancer is the No.1 killer in evening. Paul Fisher, M.Ph., Ph.D., at Virginia Commonwealth University, spoke the U.S., accounting for almost 30% of all about gene therapy and the “Cancer Terminator Virus,” which destroys cancer cells cancer deaths. Through the Muriel Ettinger without damaging surrounding healthy tissue (see Paul Fisher, page 11). Memorial Fund, Allan is raising money for This year’s tournament, which raised over $80,000 for NFCR cancer research, was lung cancer research and public education on sponsored by Calmark, Inc., with other significant sponsorships from: second-hand smoke – in memory of his mom. • Atlas Wood Floors, Inc. • MCP Chimney & Masonry, Inc. • Copilevitz & Canter, LLC • Med-Trust Online The Hope Fund for • Direct Impressions, Inc. • Merkle Inc. Sarcoma Research • Dominion Jewelers • Novad Management Consulting Six years ago, Marianne and Ken Bouldin’s • George Mason Mortgage, LLC • PhRMA daughter Jen was diagnosed with MPNST, • Folger, Nolan, Fleming, Douglas, Inc. • Premium Distributors of Maryland, LLC a rare and aggressive form of soft tissue • Key Acquisition Partners • Sage Title Group sarcoma. Says Marianne, “We listened, • Long & Foster • Tradition Title frustrated, as doctors explained the lack of treatment options available to sarcoma “We are so grateful to all of our sponsors and for the volunteers who donated their patients.” The Bouldins realized that more time to work on this event,” said Wendy Gowdey, a long-time cancer research sarcoma research was badly needed. supporter and Co-Chair of the tournament with Sarah Funt. “We couldn’t have done Fortunately, Jen made it through. But it without them, and because of their contributions we were able to raise thousands of Marianne and Ken were determined to make dollars to fund NFCR’s groundbreaking research.” sure that other families would not have to go through the same frustration. When Jen was pronounced cancer-free, Marianne and Ken established the Hope Fund for Sarcoma Research at the National Foundation for Cancer Research. “Our goal was to provide research funding for an improved understanding, and ultimately, effective treatments for MPNST and other sarcomas,” says Marianne. Their efforts are paying off. Hope Fund scientists have made several major scientific observations, one that will soon be published and two that are under review by major cancer research journals. The Hope Fund has raised over $205,000! Today, Jen remains cancer-free, and thanks to her parents’ ongoing efforts to support sarcoma research by NFCR Project Director Wei Zhang, Ph.D., at the University of Texas MD Anderson Cancer Center (see article on page 4), she and the 10,000 other patients diagnosed yearly with soft tissue sarcomas may have a better chance of living out their entire lives cancer-free.

NFCR Research For a Cure | 19 Extraordinary Support 2011 was distinguished by the extraordinary breadth and depth of support for NFCR. An unprecedented number of donors, corporations, foundations and institutions made gifts totaling $12,675,779. We are deeply grateful to all of our donors for their generosity and confidence in our vision of Research for a Cure. Every gift, large and small, is an investment in new and better ways to prevent, diagnose and treat cancer. NFCR is about cancer research, for research will cure cancer. On these pages, we are pleased to recognize those donors, corporations, foundations and institutions who made significant gifts to the National Foundation for Cancer Research in 2011. Anonymous (154) Mr. & Mrs. Tom Below Mr. John Buddig Dr. Downing Cless 5 Star Athletics The Beltman-Miller Foundation Robert H. and Janet C. Buescher Mrs. Stella N. Coates Abbott Laboratories Ms. Elissa L. Benchimol Foundation Ms. Ardis A. Code Mr. David W. Abercrombie Mrs. Muriel Benedict Mr. Justin Bugajski Ms. Florence B. Cohen Mrs. Mary R. Able Susan T. Bennett Mr. Jack W. Burkart Mr. Max Cohen Ms. Mona Ables Ms. Patricia Benson Ms. Elizabeth B. Burke Mr. Barry Cole Mr. & Mrs. Eugene V. Abraham James & Joan Berkowitz Richard & Alberta Burleigh Ms. Jennifer Cole Accureg, Inc. Mr. Donald Berlin James & Deborah Burrows Foundation Scott E. Coleridge Ms. Gertrudis Achecar Ms. April P. Bernard Mr. John Busby Mr. David P. Coley Mr. Frank W. Adams Mr. Paul P. Bernstein Mrs. Fred Busche Elizabeth S. Collins Mr. & Mrs. David Adcock Ms. Barbara Besinger Mr. & Mrs. F. Kevin Byers Mr. Tom Collins Aetna Foundation, Inc. Mr. Ajay Bhatia & Ms. Sushma Dhulipala Mr. & Mrs. Larry R. Byrd Ms. Judith Colton Mr. Farhan Ahmad Michael M. Bianco, DMD Inc. The Jack and Dorothy Byrne Foundation Combined Federal Campaign Mr. & Mrs. Bruce Alderton Ms. Judith M. Bickerstaff CaerVision Corporation Mr. John Comeau Ms. Margaret Alldredge Mr. & Mrs. Anthony Birch Mrs. Dolores Cakebread Dr. Alessandra Comini Mr. Hubert E. Allen Mr. William Bishop Calmark, Inc. Communitech Market Intelligence, Inc. Mr. Mark Allen Blackstone Valley Tech Len Camber Charitable Trust Community Foundation of Tampa Bay Ms. Sharon Allen Mr. Frank Blake Mr. & Mrs. Malcolm O. Campbell Mr. & Mrs. Sydney Cone, III The Winifred and Harry B. Allen Ms. Susan R. Blalock Ms. Martha Campbell Confraternity of Our Lady of Grace Foundation Mrs. Florence Aves Bland Mr. Michael Canahuati Connelly School of the Holy Child Mr. Obadiah M. Allmaras Debbie Blankenhorn Dr. & Mrs. Richard P. Cancelmo Mr. Kevin A. Connolly Virginia L. Alyea Mr. Anthony P. Blatnik Mr. Greg Cangialosi Mr. John P. Conte Amgen, Inc. Mr. Raymond Blessman Mr. James Canterbury Continental Operating Co. Mr. Floro R. Anastasi Mr. Jules R. Block Capitol Hill Yoga, Inc. Ms. Carol L. Cook Mr. Stephen Anbinder The Herb Block Foundation Mr. Robert H. Carboni Mr. Charles Cook Dr. Charles Anderson Blue Moon Deli Mr. & Mrs. Steve Cardenas Mrs. Gail Cooper Ms. Claudia J. Anderson Blue Sky Factory & WhatCounts Encana Cares Foundation Ms. Lillian J. Cooper Ms. Kay L. Anderson The Bluefield State College Student Carmelite Communion, Inc. Copilevitz & Canter, Inc. Mr. Travis K. Anderson Athlete Advisory Committee Calvin Carter Mr. & Mrs. Jim Cosgrove Dr. Mary Anderson-Rowland Mrs. Stacy Blumenthal Mrs. Gail Carter Mr. & Mrs. Tim Cost Mr. Ray A. Angeli Rev. Bobbie & Ron Taylor Ms. Gwendolyn C. Carter Betty L. Costa Ms. Frances P. F. Armstrong Mr. John M. Boguslawski Ms. Roseanne Carter Mr. Charles Countryman Mr. James F. Ashenden Mr. Louis J. Bonacci Mr. & Mrs. Woodrow Carter Mr. & Mrs. Michael L. Couture Atlas Wood Floors, Inc. Ms. Linda L. Bonelli Mr. Royce B. Casey Mr. & Mrs. Donald J. Cowan aTyr Pharma, Inc. Ms. Helen C. Bones Mr. & Mrs. Mike Cash Mr. Mitch Cox Mr. Curt Augustine Anita Booe & Daniel Terry Mr. Rafaela Cataedi Ms. Marjorie A. Cramer Sujuan Ba, Ph.D. Barbara Bosworth Mr. & Mrs. Avery W. Catlin Ms. Ashley F. Craver Ken & Patty Babcock Sheila M. Botelho Central Columbia High School Mr. Chadwick D. Craver Mr. John Baechle Mr. Loren Bourassa Centre College Field Hockey Ms. Lois Crawford Ms. Stacey Bailey Mr. Billy M. Brady Mr. & Mrs. Richard L. Chadakoff Mr. Jack Cronin Katrina Baker Mr. Jacques Bramhall Richard Chadwick Mrs. Ohmer Crowell Estate of Gertrude Bale Estate of Emma Brander Mr. Benedict Chan Crystal Family Foundation Mr. Robin C. Ballard Ms. Jean M. Brandt Joseph & Helena Chan California State University, Fullerton Mr. C. B. Banks Ms. Anna Mae Brannon Betty Jean Chance Mr. John E. Culkin Mr. James Banks Mr. Lloyd B. Branum Mr. William R. Chandler Ms. Nancy J. Culotta Ms. Lois H. Barker Mr. Jack Breghuis Harvey Chaplin Mr. W. W. Culpepper Ms. Laura S. Barlow Mr. Norman C. Brenneis Glenn and Angela Charles Family Mrs. Marsha C. Culver Ms. Judy Barnhard Mr. & Mrs. Winn F. Brindle Foundation Mr. Paul F. Cummings Ms. Jeanne A. Barr Bristol-Myers Squibb Company Mrs. Audrey H. Charlson Mr. & Mrs. William Curran Gino & Christine Barra Mr. Steve Broach Ben Cheek Mr. Charles W. Curtin Ms. Laura E. Barry Ms. Dorothy A. Brockhoff Mr. Hong Chen Cumi Curtis Dr. & Mrs. Robert C. Bast, Jr. Mr. Richard L. Bronson Mr. Yong Chen Cushing Academy Ronnie Bateman Foundation, Inc. Broome Community College Soccer Ho Chen Family Foundation Mr. David Dahl Alvin H. Baum Family Fund Teams Yung-Chi & Elaine Cheng Ms. Joyce E. Dakis Baxter International Foundation Estate of Clairette I. Brosen The Dr. Francis P. Chiaramonte Private Mr. & Mrs. Jeffrey Damens Mr. Robert Beck Mr. Daniel Brown Foundation Mr. John Darras & Ms. Mary E. Becton, Dickinson & Co. Trust of Frances M. Brown Mr. Richard Chinnock Mellinger Mr. C. David Bedford Ms. Jean B. Brown Mr. Kenneth Choi Leonard Dasin Ms. Mary Ruth Bedford Mr. William N. Brown Mr. Edward Choklek Mr. Allan Davenport, Sr. Mr. Bernie Beiser Trust of Jean Bruner Bob & Gloria Christopher Mr. John Davidson The Bellini Foundation Ms. Leslie Brunk Chua Charitable Foundation Ms. Anita L. Davis Beloit College BT Americas, Inc. Marie R. Cimino Ms. Arlene Davis Clayman Family Foundation Lana R. Davis

Includes all donors, foundations, corporations and institutions giving $500 or more between January 1, 2011 and December 31, 2011.

20 | NFCR Research For a Cure Mr. & Mrs. Richard Davis Fairview High School Dr. Joseph R. Godzik Mr. Harold U. Hernandez Ms. Marcy De Faria Pamela M. Falge Mrs. Verne A. Goeppinger Mr. Richard Hersh Dedham High School Mr. Santiago C. Soler Favale Ms. Jamie Goff Howard F. & Joan K. Higley Gift Fund Mr. Douglas S. Dedrick Mr. & Mrs. Mark Feder Mr. David R. Gold Larry & Sharon Hilgeman Jacob & Jill Deeds Feibelman Family Mr. Allen Goldberg Mr. Charles D. Hill Jorge I. & Kara Mae Del Valle Dr. and Mrs. Jules A. Feledy, Jr. Mr. Rafael Gomez Mrs. Sara S. Hill Mr. Daniel DeMatteo William & Dione Fenning Good Cause Greetings, Inc. Mrs. Tom Hill Trust of Grace W. Densmore Ms. Elaine Calevas Ferat Mr. & Mrs. Andrew D. Goodman Sanford J. & Penny Hillsberg Depauw University Mr. & Mrs. John Ferguson Mr. James Goodwyn Rose M. Hodel Ms. Sylvia Desantis Mr. Frank P. Fetters Ms. Louise Goos Lynn Hoeppner Mr. & Mrs. Joseph M. DeSarla Mr. Ronald C. Fettig Mr. & Mrs. Dwight Goossen Mr. John Hogan Jan W. Deweerd The Feuerring Foundation Ms. Carol E. Gordon Mr. Ronald Holert Mr. Charles Dexter Bryant Bulldogs Field Hockey Mr. & Mrs. John Gordon Mr. & Mrs. William J. Holland Paul J. & Victoria A. Diaz First Baptist Church Mr. Robert B. Gordon Dr. & Mrs. Eric Holland Estate of Silvia Dibenedetto Mr. Matthew Fisher Mr. Dirck W. Goss Trust of John T. Holowiak Trust of Gertude F. Dickson Dr. Paul B. Fisher Mr. Peter W. Gowdey Ms. Marilyn Hondorp Eileen Diemand Foundation Mr. Edmond Fitzgerald Mrs. Wendy Gowdey Dr. Waun Ki Hong Ms. Alissa Dietz Mr. Fred Fitzhugh Ms. Joyce B. Grabner Mr. J. David Hood Julie Dike Mr. & Mrs. Lowell S. Fixler Mr. Joshua Grady Mrs. Lexalynn T. Hooper Mr. Collett B. Dilworth Mr. Aaron Flautt Grainger, Inc. Mr. Brian Hoskins Ms. Kathleen M. Dineen Dr. Arthur Fleischer Mr. David H. Gray Heather C. Housman Direct Impressions, Inc. Mrs. Blair S. Fleischmann Susan Greally Ms. Dorothy Houston Ms. Sara Dobbertien Ms. Dianne Fleming Mr. William Green S. L. Huang Charitable Foundation Mr. Todd Dodson Ms. Amber Flynn Greenville College Trust of Leonard & Eustelle Hudson Mr. Scott E. Dolan Mr. Patrick J. Foley Mrs. Edna W. Gregg Stephanie Hughes Mr. John Dollard Mr. Dave Foltz Mr. Steve Gregg Mr. James M. Humber Ms. Lauren Dominguez Mr. Peter Formato Mr. & Mrs. Watson W. Gregg Mrs. Anna L. Hume Donate for a Cause Ms. Julia B. Forrester Dee Ann Gretz Dr. Mien-Chie Hung Donegal Field Hockey Booster Club Mr. Gerald R. Forsythe The Shirley W. & William L. Griffin Ms. Mary Ann Hunt John C. Donnelly Mrs. Kathleen Foster Foundation Dr. Amy S. Hunter Mr. & Mrs. Matthew Donohue Ms. Genevieve Fox Griffith Energy Services, Inc. Ms. Ilene Hutchins Muriel Dorking Mr. James Fox Gisela W. Grosse Mr. Charles Hutchinson Mr. Francis H. Doughty Mr. Jonathan W. Fox Trust of Wilbur C. Grosse Ms. Patricia Hyde Mr. Christopher Douglas Fox Chase Cancer Center Mr. & Mrs. Jay M. Grossman John L. Iacobelli, Ph.D. Folger Nolan Fleming Douglas Dr. Richard Fraioli Mrs. Jeanette Gubser IBM Employee Services Center Mr. Hugh W. Downe Mr. & Mrs. Gary Bob Fraley Mr. Gerald H. Guinn, Sr. Mr. & Mrs. Peter Indovina Mr. & Mrs. Griffith Doyle Ms. Maria Franco Russ & Andrea Gullotti Charitable Ms. Josephine F. Ingle Michael J. & Cheryl L. Doyle Mr. Harold Frank Foundation Ms. Judy Inserra Mr. Martin Drey Mr. M. Joshua Frank Mr. George Haas Mr. Scott Intravia Jon Drowns James & Jennifer Franke Mr. & Mrs. Charles Hadley Ms. Nancy S. Itteilag Mr. Matthew A. Duda Mr. Aaron Frankel Mr. Gerry Hagar Mr. A. Willard Ivers, Jr. Mr. Frank X. Duffy Mr. & Mrs. Joseph F. Franlin Mr. William R. Haines Mr. David G. Ives Trust of Mildred R. Dumbauld Joan K. Fratar Mr. Everett L. Hall, Jr. Krish C. Iyer Ms. Aurelia Dunagan Free Family Foundation, Inc. Mr. James M. Hall Bahija Jallal, Ph.D. Mr. Robert T. Dunn Mr. & Mrs. Andrew Frei Ms. Elaine Haller Ms. Kathleen Jeffries Mr. Wayne Dutt Ms. Joyce Froot Ms. Margaret Halvorson Mr. Ernest Jensen Dr. Harold L. Dyer Mr. & Mrs. Andrew Funt Mr. Dan Hamelberg Mr. Aldon Johnson Mrs. Lois W. Dyk Mr. Gerald Furner Mr. Gerald E. Hamilton Mr. John Johnson East Surry High School Patricia S. Gabriel Hampton Roads 7 Cities Pro-Am, Inc. Mr. Keith Johnson Eastern Iowa Community College District William A. Gage Mr. Hammond H. Han Ms. Melissa Johnson Bonnye Eastwood The David E. Gallo Foundation Jo Ann G. Hanaway Susan M. Johnson Mrs. Betty A. Eberle Gallia Academy High School PTO Mr. Eric D. Harbison Mr. Thomas Johnson Mr. H. Dennis Edwards Mr. Daniel P. Garcia Mr. Joseph Hardick Johnson & Johnson Mrs. Mary Edwards Mr. Leon Garden Mrs. Sulabha V. Hardikar Mr. Michael Johnston Mr. & Mrs. Samuel Edwards Trevor & Susan G. Gardner, Jr. Ms. Roberta Harding Ms. Bernadine C. Jones Anthony J. & Kristen J. Eggert Mr. Robert M. Garneau Mr. & Mrs. Joe B. Harford Estate of Gordon K. Jones East Grand Rapids Field Hockey Dr. James T. Garrett Mr. William Harlan Mr. Robert C. Jones Ms. Frances Ehrlich Mrs. Lucille H. Garrett Mr. Lindsey Harmon, Jr. Mr. Thad M. Jones Mr. Ted Eiben Mr. Robert W. Garthwait, Sr. Keith Harpster Mr. Thomas M. Jones Ms. Amy Eidelman Lynn J. Gauger Mrs. Iwalani W. Harris Ms. Catherine S. Jordan David & Rachel Eidelman Mr. & Mrs. John R. T. Gautrey Ms. Mary Jo Harrison Dr. William L. Jorgensen Ms. Ardemis Ejdaharian Mr. Norbert Gehr Ms. Lynn Hart Mr. Kent Joshi Eli Lilly & Company Ms. Kristina Geissler Ms. Margaret S. Havens Ms. Sharon Joshi Dorothy F. Elicker Genentech Haverhill High School T. D. Jotcham Mr. & Mrs. John E. Elicker, Jr. Georgetown College Edwin F. & Noriyo Hawxhurst Ms. Judy M. Judd Lee S. Elliott Mr. Joseph D. Georgianna Mr. Mark Hayley The Jurenko Foundation Mr. Frances M. Ellison Mr. & Mrs. Paul Gerwin Dr. Arthur F. Hebard JustGive Mr. Joseph F. Emig Dr. Patricia A. Geuder Mr. Orin Heend K & L Crabs Ms. Mayte C. Eriksson Mr. & Mrs. D. J. Ghilarducci Janet E. Helms, Ph.D. Sherry and Stewart Kahn Fund Ms. Josephine Espinoza Mr. David Gibson Estate of Carmen Henle Padmakumar Kaimal, Ph.D. Allan R. Ettinger Foundation Ms. Elizabeth Needham Giuliani Ms. Raquel Henry Sree Kaimal, Ph.D. Ms. Anne Evans Mr. & Mrs. Anthony L. Giustini John F. & Lisa G. Henschel Mr. Duane Kakazu Estate of Cecil C. Evers Michael Glass Mrs. Donald F. Herbst Dr. & Mrs. Steven P. Kalter Mrs. Marcia E. Fabbro Mr. & Mrs. Norman Glaze Estate of Velma Herdlick The Kandell Fund

Includes all donors, foundations, corporations and institutions giving $500 or more between January 1, 2011 and December 31, 2011.

NFCR Research For a Cure | 21 Mr. Laverne Kane Mr. Darren Levine Mr. Joseph Mathis Daniel Morter Dr. Young Kang Mrs. Sheba Levine Mrs. Margaret Maw Mr. & Mrs. Andy Moses Mr. Jared Kaplan Mr. Steven Levy Mr. Robert Maxwell Ms. Della Moulson Karpet King Ms. Paula Lewandowski Ms. Shirley McBee Mr. James R. Mudd Candace Karu Mrs. Wyonne J. Lewitz Ms. Patricia McCauley Mr. Yevgeniy Muravchik Ms. Elizabeth Kasimow Liberty Mutual Foundation Ms. Anna McClure Scott Mr. David Murphy Janet L. & Robert J. Kass Libertyville High School Mr. Raymond McCurdy Estate of Elizabeth S. Murphy Kristin Kaurich Mr. Michael J. Lichtman Mr. Bill McFadden Dr. John Murphy The Kay Family Foundation Mr. & Mrs. Gerald Lieb Mr. Joseph P. McGovern Mr. Jeff Murray Mr. Alan P. Keeny, Jr. Pete & Shu Lim Mr. Robert A. McGrann Mrs. Nancy A. Murray Mr. William E. Keller Mr. Steven Limbert The Howard & Kennon McKee Ms. Shirley L. Musselman Mr. Jeffrey B. Kempic Mr. Chuan-Jay Lin Charitable Fund Mr. John B. Myers, Jr. Mr. Jeffrey Kenneson Mr. Angel D. Linares-Lugo Ms. Debbie McKenzie Dr. & Mrs. Robert Myers Mr. & Mrs. Deryck Kent Estate of Roger & Anna Lind Mrs. Corenne M. McKinley Mrs. Ann Myers Williams Lawrence J. & Mary Kent Mrs. Frances M. Lindsay Mr. Jim McNulty Mr. Joseph Myrtetus Kentucky Country Day School, Inc. Powell & Malinda Lindsay Patrick S. & Toni McNutt Ms. Janet Myruski Benvenuti Kerrie Mr. & Mrs. Charles Lindsey MCP Chimney Sweeps, Inc. Mr. Rehan Naqui Mr. & Mrs. Kenneth L. Kerzner Mrs. Peggy Linger Mr. David E. Meade National Engineering Products, Inc. Mrs. Ethel E. Kessler Ms. Katherine A. Linneman Medco Health Solutions, Inc. Ms. Lois M. Naylor Mr. Randy Kettering Ms. Lori Lins Mr. Heinrich Medicus Mr. & Mrs. Paul Neale, Jr. Ketterman’s Jewelers Mr. Frederick Lister MedTrust Online, LLC Mike Neigoff Key Acquisition Partners, LLC Mr. & Mrs. Joel Litman Mr. Patrick Meehan Mr. James P. Nettleton Mr. Allen D. Kimmel Litterman Family Foundation Mr. Jitendra Mehta New England Phoenix Fastpitch Mr. Patrick F. Kindelan Mr. Pierce Lively Ms. Caridad Mejusto Organization Mr. & Mrs. Thomas King Chris Lloyd & Arleen Sorkin Mr. Elliot Melamed Mr. Mark D. Newman Mr. James Kinter Ms. Betty Locke The Elena Melius Foundation Mr. Steven Newman Sibyl Kirby Mr. Charles S. Locke Ms. Masifa Meme Mr. Khanh Nguyen Mr. & Mrs. Richard W. Kirshenbaum Ms. H. E. Lodholz Merck The William & Diane Nitterhouse Ms. Margaret Kitchings Dr. and Mrs. Robert Loeb Marian Merkey Foundation Mr. Rion Klawinski Mr. Scott Loney Merkle, Inc. Mr. Raymond Noble Mr. Arnold Klein Longacre Appraisal & Adjustment Service Mr. Leon S. Merrill, Jr. Mr. & Mrs. James R. Nolan Mr. Ralph Kluesner Ms. Jane H. Loo Mr. & Mrs. Brian S. Messenger Mr. James Nolting Ms. Jane M. Kneessi Mr. & Mrs. Raymond Lopez Mr. Stuart Meyer Ms. Tina Nordlander Knights of Columbus Council 7941 Mr. Bernard Loredo Mr. & Mrs. Bill Michalewicz Lake Norman High School Tara & Robert Koffman Mr. & Mrs. Lee Loughnane Mr. Robert W. Michel North West Guilford High School Mr. & Mrs. Joseph Koo Mr. Bruce A. Loughran Microsoft Mr. Arden L. Norton Koopman Dairies, Inc. Mr. Scott H. Lounsberry Mrs. Frances Milberg Mr. Richard C. Norton Mr. & Mrs. Ronald F. Kornell Trust of Edward Low Ms. Brenda K. Miller Mr. Scott A. Norwell Ms. Kimberly Koury Ms. Donna Lozar Mr. Jay W. Miller Nour Foundation, Inc. Kraft Foods Mr. Tak-Ko Lu Mr. Jim Ed Miller Novad Management Consulting Mr. Bill Kramer Mr. Francesco A. Lucarelli Ms. Lisa Miller Mr. Charles Novak Mrs. Sandra Krause Scott & Susan Lucas Mrs. Mary Anne Miller Novartis Pharmaceuticals Corp. Ms. Dorothy E. Kring Dr. & Mrs. Milo Lundell Victoria Miller Joseph & Abby Nussbaum Ms. Echo Son Kuan Mr. Nathan Lustman Ms. Elizabeth A. Mills Estate of Helen Nye Casey Kujawa Luther College Softball Team Christian Milton & Rana Nikpour Flora May W. Nyland R. J. Kunik & Company, Inc. Mr. David Lyons Susan L. Miltz O’Connor Family Foundation Mr. Richard Kurland Mr. Kwok Tung Ma Mr. Bernie Minsk Mrs. Ruth H. O’Dea Ms. Dolores Kusmiersky Mr. Stewart MacAulay Mr. Jonatas Misaka Mr. Thurmond Oliver L & E Meridian Mr. Roger I. MacFarlane Missionary Sisters Ms. Erin A. O’Neil L S Investment Advisors MackayMitchell Envelope Company Mr. & Mrs. James Mitchell Miss Liping Kathy Ong Todd LaBorwit Mr. Bruce K. Mackie Michael J. & Sharon Modiz Mr. R. David Orr Mr. Adam Ladd The Madeira School Estate of Florence M. Monroe Mr. Edgar Ortiz Dr. Brooke Laduca Mr. James Madej Mr. Masoud Mohseni Matt & Melissa Orwig Mr. Marvin Lagarde Ms. Carole Mahoney Monroe Community College Association Nessa O’Shaughnessy Mr. David E. Lambert Dr. Tyler X. Mahy Lisandro Montalvo-Sanchez OSI Pharmaceuticals, Inc. Ms. Elizabeth W. Lamond Trust of Susan Mahn Al & Anita Monty Ottawa University Ms. Sue Lampson Ms. Millicent F. Mailliard Mrs. Sharon Mooney Mr. W. Kent Oyler Ms. Jean L. Lancaster Mr. Denver E. Maine Ms. Cheryll Moore Mr. Rudy Pachl Richard Landesman Jane & Simon Mak Ms. Lois Moore Mr. Gene Pagnozzi Mr. & Mrs. Michael Lane Mr. Richard Mallery Ms. Martha Moore Estate of Elmer Palm Ms. Saraellen M. Langmann Mr. John F. Manning, Jr. Mr. Stephen Moore Harold & Marlene Palmer Mr. Jerry A. Larson Mr. Silvian Marcus Mr. & Mrs. Tye Moore Mr. Leo E. Pardo Mr. Vito M. Lastella Mr. Lee Margolis Mr. & Mrs. Dan J. Moran, Jr. Carolyn Pare & Sharon Connel Mr. & Mrs. David R. Latchford David & Mona Markus Mr. Donald Moran Mr. Siddharth A. Parekh Nimitta & Apur Lathiya Family Gift Fund Mr. & Mrs. John P. Marren Moreau Catholic High School Ms. Twila A. Paridon Dr. Jean C. Lauricella Mr. Francis Marriott Araceli Moreyra Estate of Geraldine Parker Dr. Asuncion Lavrin Mr. John W. Mason Anne M. & William A. Morgan Mr. John Parrish Mr. Richard E. Le Boeuf Dr. Sanford Mason Jeffrey & Marcia Morgenthaler Mr. Tejash M. Patel Mr. David M. Leaf George Mason Mortgage Mr. Andrew S. Moroz Mr. Philip E. Patrie Mr. & Mrs. Richard M. Leder Paul R. & Donna Masse Mrs. Bonnia L. Morris Ms. Joanne H. Patton Rachael Legath Mrs. Edith Massey Robert Morris University The Paulits Foundation, Inc. Mr. Clyde E. Lehman, Jr. Mr. & Mrs. Richard Masson Janice Coppage Mortenson Family Fund PebbleCreek Ladies Golf Association Mr. William G. Lerch Mr. Carlos Mastrangelo of The Greater Cincinnati Foundation Cancer Awareness Tournament Trudo Letschert Ms. Betsy B. Mathiesen

Includes all donors, foundations, corporations and institutions giving $500 or more between January 1, 2011 and December 31, 2011.

22 | NFCR Research For a Cure Col. Clifford J. Peabody Ms. Katherine Reynolds Mrs. Kathryn Schulberg Mr. H. Ellsworth Steele Mr. Ronald Pelletier Ms. Jane Rhodes Seago The Susan and Ford Schumann Mr. & Mrs. Don Steenerson Paul & Rose Perfect Ms. Carolyn Richards Foundation Karen Stein & Jerry Hyman Estate of Naomi F. Perius Ms. Joyce C. Richards Mr. Perry Schwartz R. J. M. Stein Family Foundation Alex Perlin Stephen & Kathleen Richards Ms. Jan Scott Estate of Frederika Steiner Mrs. Eileen Perpiglia Mr. Randolph E. Richardson, Sr. Ms. Lavina D. Scott Mr. David Stern Ms. Maria T. Pessano Mr. & Mrs. Alan Richstein Mr. & Mrs. Vincent E. Scully Ms. Rebecca Stern Ms. Mary Peters Stella Ridilla Mr. Ricky L. Senitza Paul Stevens Ms. Gail M. Peterson Dr. Diane M. Ridley-White Louis & Cyn Seo Dr. Henry Steward Ms. Evthokia Petrikkou Mr. Kenneth Ringbloom Joaquina Sepulveda Estate of Blanche L. Stewart Dorothy Pettersen River Valley High School Mr. Alvin Settle Lt. Col. Douglas D. Stewart, USAF (Ret) Mr. John A. Pettus Mr. James Rivera Sewanee: The Univerity of the South Mr. Lawrence E. Stewart Pfizer, Inc. Daniel Rivera-Gomez Gregory J. & Jennifer Shaia Mrs. Lynn A. Stewart Elizabeth M. Pfriem Mr. & Mrs. Donald Roache Mr. James A. Shanley Mrs. Charlotte P. Stobart PhRMA Mr. & Mrs. Paul Roberts Mr. & Mrs. David Shatzer Susan Stoddart Estate of Alice M. Pickering Mrs. Lois M. Robertson Ms. B. J. Shea Ms. Suzette I. Stoler Arte I. Pierce Ms. May A. Robinson Russell & Betty Sheets Mr. Jay Stolper Mr. & Mrs. Charles E. Pierce Mr. John Roche Dr. David D. Shepard Jean M. Stout Mrs. Linda J. Pierret Mr. & Mrs. Stanley E. Roegner Mrs. Geraldine Sherwood Mr. Robert M. Strong Vitality Pilates Lee & Alice Roest Ms. Patricia J. Shimek Mr. & Mrs. David C. Stump The Jana E. Pinker Memorial Foundation Ms. Melody Rogers Mr. Steve Shira State University of New York at Oswego Mr. James Piper Mr. Thomas L. Roller Ms. Deepa Shirali Women’s Field Hockey & Lacrosse Estate of Kimberly Ann Pisarra Mr. John F. Romanowich Gen. Raymond L. Shoemaker Mr. & Mrs. Thomas Sutphen Plains Marketing, LLP Anne & Corey Romanowski Ms. Suzanne Shoemaker Ms. Barbara Sutton Paul & Julie Pokorny Ms. Beatrice Rosenberg Sacred Heart University Field Hockey Mr. William L. Swager Mr. & Mrs. Ira Polk Selma Rosenberg Shulman, Rogers, Gandal, Pordy & Ecker, Eugene L. & Carole J. Swaney, D.D.S. Mr. & Mrs. Craig Pollen Mr. & Mrs. Jay K. Rosenblatt P.A. Mr. Donald A. Swanson Ms. Mary L. Polo Ms. Sally R. Rosenbluth Mr. & Mrs. David Siegel Mr. & Mrs. Marvin R. Swanson Mrs. Kathryn Polster Dr. Alvin Rosenfeld Mr. Jeffrey Siegel Mr. Gregg Swartz Mr. Gustav Popke Mr. Charles G. Rosenfelder Mr. Robert G. Siegel Susan E. Sweet Mr. Robert Porod Ms. Sheryl A. Rosine Mr. Joe Sileo Mr. Robert A. Swenson Mrs. Cynthia W. Porter Mr. Robert Roslawski Teresinha Simoes Capt. W. R. Swindells Mr. Robert F. Porter Ms. Johanna Ross Mr. Daniel Simon Shehryar & Sameera Taher Ms. Darla Postil Royal Production Company, Inc. Mrs. Morene L. Simon Ms. Barbara Tanase Mr. Ward Potts Martha & Max Rubinstein Family Charles H. & Shirley B. Simpson Tandem Products, Inc. Deborah A. Poulter Foundation Foundation Richard Tanzmann & Donald Herbert Ms. Christine Powell Mr. & Mrs. Carl F. Ruble Col. Paul N. Sims (Ret.) Paul & Juanita Tarantino Mr. & Mrs. Ralph Powell Mrs. Joyce Rucker Ms. Alisa M. Singer Mr. Douglas Taylor Ms. Kathryn Powers Archibald & Frances Rufty Foundation Ms. Diane Sipics Trust of Mabel Taylor Jeffrey Poznick & Ula Swenson Mr. Daniel Rugg Mr. Thomas M. Sipkins Marilynn Taylor Prairie Island Indian Council Virginia D. Rushmore Mr. Richard Skalski Mrs. Nancy B. Taylor Mr. & Mrs. Anthony C. Pratt Ms. Cynthia Russell Mrs. Carol Skanse Mrs. Suzanne F. Taylor Ms. Mary Predel Mr. David Rutter Ms. Doris E. Slavin Rita S. Thalacker Premium Distributors of Washington Mr. Timothy J. Sacheck Mr. & Mrs. David Slawson Virginia L. Thomas Mickey & Sandi Preston Sage Title Group, LLC Ms. Roberta Sloan Mr. Colin R. Thompson The Price Family Foundation Mr. Fanklin C. Salisbury, Jr. Mr. & Mrs. Bernard Smith Ms. Miyoko Thompson Estate of Nancy B. Price Mr. Fred S. Salisbury Dr. & Mrs. Dennis Smith Ms. Teresa A. Thompson Wayne L. Prim Foundation Mr. Nazareno Salvaterra Mr. Glenn Smith Mr. Charles W. Thomson Production Management Group Ms. Adriana Samper Mr. Jarod Smith Joan E. Thornton, M.D. Mr. James S. Prokay Ms. A. Sue Samuels Ms. Margaret Smith Thos. Somerville Co. Mr. Marco Pulido Estate of Henry E. Sanders Mr. & Mrs. Mike Smith Anna Marie & John Thron Ms. Carlene Putler Mr. & Mrs. Joel Sanders Mrs. Phyllis V. Smith Marlene Tietjen Ms. Hazel H. Quick Mr. Steven Sanders Robert & Merilyn Smolinski Ms. Maria Tillan Ms. Irma Quiroga Mr. Bradley Phillip Sandidge Mr. Loren Snyder Mr. Fred Tillman Mr. Greg P. Rainbolt Ms. Yoriko Saneyoshi Mr. Walter H. Sokel Mr. Donald Timm Sadashiv Rajadhyaksha Mr. Robert E. Sanson Mr. Lawrence J. Solari, Jr. Mr. & Mrs. Ronald R. Tisch Mr. Farid Ramezanzadeh Flavio & Irene Santoni Estate of Irene Solonsky Mr. Carl Tisone Mr. Jeffrey M. Ranew Ms. Melinda Sarli Wehrle Ms. Erica Sorensen Mr. Robert Tonnancour Delores Ranz Mr. Bill Sayre Ms. Nancy B. Soulette Topaz Mortgage Corporation Mr. Ken Raphael Mr. Thomas Scanlan Mr. Roger Souter Dr. Keith Torke Mrs. Rosemary Rasmussen Mr. & Mrs. Benjamin Schafer Southern Virginia Recreation Facilities Ken-Ichi Toyama Mr. Michael Ravin Mr. & Mrs. Craig Schaum Authority Tradition Tile, LLC Razoo Foundation Maj. Charles P. Schell, Jr. (Ret) Ms. Davida Sparks Mr. & Mrs. John M. Trani Redfield & Company Mr. Elliott Schiffmann Mr. Charles H. Spaulding Mr. Roy H. Tunby Mr. H. Edward Reed The Albert G. & Olive H. Schlink Mr. & Mrs. Jerome Spector Mr. & Mrs. Jerry Turner Ms. Lynda Reed Foundation Ms. Aimee Spoerlein Wm B. Turner Susan Regisford, M.D. Mr. Sheldon Schmertzler Mr. Keith A. Springer Tyco Corporation Mr. David Reichardt Mr. Douglas Schmidt Mr. Christopher Stacklin United Way of America Ms. Jurema Reis Mr. Paul Schneider Dr. Jan Stallaert & Dr. Sulin Ba University of Saint Francis Mrs. Mary Grace Remeikis Mr. Thomas Schneider Anna Stanfield Mr. Charles Urban Mr. Cornelis J. Rensburg Ms. Silvia Schnur John S. & Lucy E. Stanovick Mrs. Genevive Valeri Trust of A. L. & E. R. Repecka Mrs. Joan E. Schraml Paul R. Stanovick, D.D.S., P.C. Valley Christian Schools Retirement Planners & Administrators Trust of Albert C. Schroeder Trust of Toby Starr Mr. Harry Van Iderstine Mr. & Mrs. Donald R. Reynolds Mr. James A. Schroeder Mr. Joseph Stas Mr. Hubert H. J. Van Nes

Includes all donors, foundations, corporations and institutions giving $500 or more between January 1, 2011 and December 31, 2011.

NFCR Research For a Cure | 23 Jerre Vandenbent Mr. Jason Wanderer The Martha F. Wells Family Foundation Curtis Woodhead & Susan Rossetti Mr. Robin Vandermolen Mr. James Wangler Ms. Theresa Welsh Mr. George E. Woods Mrs. Barbara Vandervalk Ms. Shirley Wann Gary C. & Rosemarie Wendt Mr. Larry Woody The Peter & Anna Vanderveld Foundation Mrs. Hazel J. Ward Donna Wernecke Elementary Mr. & Mrs. Steve Wrench Mrs. Lindsey H. Vereen Mr. Samuel F. Ward, Jr. Ms. Mary J. Wertheimer Mr. Mark Wright VFW A.E.M. Post 4287 Ware Blue Grass Foundation, Inc. Mr. Jay Wessels Mr. & Mrs. Paul Wright Villanova University Mrs. Thelma M. Warren Mr. Robert Westwood Mr. Donald W. Wruck Mr. Kenneth B. Virnig Ms. Kristi Wasson Betty Shaw Weymouth Mr. Pierce Wynne Visa Mr. Robert H. Watkins Mr. George L. Wheat Mr. & Mrs. Robert Wysocki Mrs. Mona Vollmer Mr. David P. Watson Andrea D. White Mrs. Amy Yamamoto Mr. Fred K. Von Hillebrandt Mr. Elliot R. Wax Edith M. White Mr. Sueo Yamashita Dr. & Mrs. Daniel D. Von Hoff Waynflete School Whiting Foundation Mr. Eric Yap Mr. James B. Voyles Mr. Jeffrey C. Wear Anthony Wilkinson Mrs. Pat Yee The Wagner Foundation Estate of Elizabeth Weaver Mr. & Mrs. Steven Will YM BioSciences, Inc. Mr. Andrew Wales Mr. William L. Weaver Estate of Doris M. Willett D. Yorichi Mrs. Marguerite A. Walk Mr. Mike L. Weber Mr. Nolan E. Williams Mr. Bill Young Estate of Josephine Walker Ms. Sylvia J. Weeres Charlene Wilson Ms. Donna Zaballos Mr. Walter J. Walker Mr. Louis Weinkle Ms. Virginia Wilson Dr. Charles M. Zacharias Mrs. Willard J. Walker Ms. Deborah Weiss Ms. Dorothy Winkey Ms. Mary Z. Zemon Mrs. Joy Anna Wallace Mitchell & Linda Weiss Bill & June Winn Foundation Mr. Suiyuan Zhang & Ms. Sumin Ba Mr. Josh Wallach Dr. Danny R. Welch Ms. Alice Wiren R. Zimmerman Jean L. & Erin J. Walsh Mrs. Ellen C. Welch Mrs. Frances Witt Edith A. Zimmermann Mrs. Melissa L. Walsh Ms. Thelma Welch Mr. & Mrs. John C. Wojick Ms. Lisa Zirkin Mr. Myles E. Walsh Mr. Kendall H. Wellman Mrs. Lynn Wolfson Mr. Andris A. Zoltners Ms. Stephanie S. Walsh Wells Fargo Ms. Leslie Wong Arnold Zukow, M.D. Mrs. Shirley J. Walthall

Includes all donors, foundations, corporations and institutions giving $500 or more between January 1, 2011 and December 31, 2011.

Legacy society donors The Legacy Society recognizes donors who have chosen to create a substantial legacy in cancer research by leaving a gift to NFCR through their estate, or by utilizing other planned gift vehicles to support NFCR’s cancer research. We are grateful to these donors for their dedication and foresight and are proud to recognize them through membership in the NFCR Legacy Society.

Anonymous (3) Ms. & Mrs. Donald J. Cowan Mr. & Mrs. Robert Koch Mr. & Mrs. Francis Plumb Mr. & Mrs. Lyle M. Adams Mr. John P. Cowden Mr. Ernest A. Kosow Ms. Kathryn Powers Mr. & Mrs. Terry E. Albrecht Mrs. Thomas A.Crawford Mr. & Mrs. Edward Stanley Krejci Ms. Debra Putnam Ms. Linda Appel Ms. Connie S. Cunningham Marion Kremen, Ph.D. Miss Monique C. Rainville Mrs. Mary G. Arnett Mrs. William P. Curto Ms. Harriet LaClare & Mr. Don Mills Rev. Robert J. Carlson Sujuan Ba, Ph.D. Mr. & Mrs. Ted Czajkowski Ms. Bridget Mary Landry Ms. Janet Robbins Ms. Gertrude J. Bailey Mr. Jose Davila Mr. & Mrs. Billy B. Lawrence Mrs. Janice M. Roof Ms. Gloria Barry Mr. Paul Dayhoof Mrs. Becky C. Lee Mrs. Sandra C. Rowe Mrs. Cordelia Bennett Mrs. Lois N. De Conca Ms. Madeline Lester Mr. & Mrs. John L. Rust Mrs. Annette Berman Ms. Karen Deck Mr. John R. Limpus Mr. Franklin C. Salisbury, Jr. Mr. & Mrs. Roger A. Berube Mrs. Teresa Duckett Linda L. Clark Ms. Vivian B. Sherman Ms. Christina Billiard Mrs. Dorothy Evans Ms. Elana Lippa Mr. Lewis R. Shields Mr. & Mrs. Jerry Bleeker Mr. Elmo L. Fischer Mr. Joseph J. Lisboa Dr. David P. Sickles Ms. Florence Bliss Mr. David J. Frederickson Mr. Haughton Livesey, III & Mrs. Livesey Ms. Judy Simon Mr. Jack Bollinger Ms. April C. Garry Mr. Earl McKinley Mr. & Mrs. Douglas R. Snowden Mr. David T. Bonney Mr. Donald R. Gemmel Ms. Mary C. Majewski Mrs. Margot I. Sparling Mr. Moses Bradford, Jr. Ms. Louise R. Geretti Mr. Ionel Marsavela Shirley Starr Mr. Dennis Brogan Mr. & Mrs. Dean Gettemy Ms. Sherril Metzger Mr. Isaac R. Suarez Mr. Ronald A. Brough Mrs. Sydelle Goldwurm Mr. Eric Milsted Mrs. Sonia E. Supple Lois M. & Robert Burns Mrs. Deborah Goodwin Ms. Mary Elizabeth Moore Mr. Roy L. Tanksley Ms. Maryann A. Buruchian Lydia Grundahl Mr. Cruz Moreno Ms. Lynn N. Truong Mr. Paul Bury Mr. & Mrs. Gordon Gutkowski Ms. Linda Nedelman Ms. Trudy Ullman Mrs. Deborah Caballero Ms. Patricia Hale Mrs. Lillian R. Neff Mr. & Mrs. Fred Unterleitner Mrs. Thelma D. Cabaniss Ms. Martha Hall Mr. & Mrs. James R. Nolan Mr. Charles Uphoff Rev. Robert J. Carlson Miss Barbara Hammonds Mrs. Ruby D. Norwood Mr. Charles Urban Ms. Aliyssa H. Chanthakhounsy Mr. & Mrs. Herbert L. Harger Mrs. Ruth H. O’Dea Dr. & Mrs. Daniel Von Hoff Ms. Andrea Chaulklin Ms. Treva Hobson Mrs. Charlotte S. Olsen Ms. Mildred Wald Mr. Vincent J. Chellsen Marie D. Hutchinson Mr. Albert Ottinger Ms. Ruth Walters Marie R. Cimino Ms. Bette Israel Mr. & Mrs. Randy Palmer Ms. Deborah Weiss Ms,. Linda L. Clark Sree Kaimal, Ph.D. Mr. Joseph Parham, Jr. Ms. Marilyn Wewerka Mr. Steve Clutter Mr. Charles W. Kent Ms. Naomi F. Perius Ms. Leonilla Zobs Mr. Stanley H. Cohen

Includes all qualifying legacy society members between January 1, 2011 and December 31, 2011.

24 | NFCR Research For a Cure NFCR Board of Directors

Chairman Mark Baran Padmakumar Kaimal, Ph.D. Judith P. Barnhard, CPA Managing Director Vice-President Partner Four Springs Capital, LLC Technology Alliance & May & Barnhard, PC New Jersey Business Development Maryland Suven Life Sciences Scott E. Coleridge New Jersey Michael Burke, CPA Managing Director Managing Partner Healthcare and Life Science Investments Richard Perry Yorke, Burke & Lee, PC Morningside Technology Advisory, LLC Founding Partner Maryland Massachusetts Veritus Group New York

NFCR Board of advisors

Abraham Amoros Judith A. Franlin William Potter Chief of Communications Philanthropist and Community Activist President Office of the Governor Pennsylvania Robert R. Meredith, Inc. Pennsylvania New York Sarah Funt Marianne Bouldin Realtor Anne Rouse Co-Founder Long & Foster Realtors NFCR Volunteer Hope Fund for Sarcoma Research Maryland Virginia Washington, DC Ken Hansen David M. Sotsky David K.G. Chan Sr. Director Director Chairman/CEO Registry Services, Business Development Institutional Group Asian Chamber of Commerce Neustar, Inc. Convergent Wealth Texas Virginia Maryland

Nancy Flood Cole Richard Mallery, Esq. Lucy Stanovick, Ph.D. Special Events Consultant Managing Partner Associate Professor Maryland Snell & Wilner, LLC East Stroudsburg University Arizona Pennsylvania Allan Ettinger Senior Vice President –Wealth Management Mary Ann Miller Brian Vogel Senior Investment Management Consultant NFCR Supporter ISG Operations MorganStanley SmithBarney New Jersey MorganStanley Illinois Maryland Stephen Minar Joseph F. Franlin Research Analyst Co-Founder MorganStanley Neustar, Inc. Connecticut Pennsylvania www.nfcr.org

Research curEs cancer All Types of Cancer

4600 East West Highway |Suite 525 | Bethesda, MD 20814